Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30466820 | 1.00 | EPHX2 (0.40) | EPHX2KMT2AP2RX7KDM4EMDM2 | |
| SCHEMBL29639579 | 0.86 | EPHX2 (0.41) | EPHX2KMT2AP2RX7KDM4EMDM2 | |
| SCHEMBL29639589 | 0.86 | EPHX2 (0.42) | EPHX2KMT2AMDM4TP53CASP3 | |
| SCHEMBL21677939 | 0.86 | EPHX2 (0.42) | EPHX2KMT2AMDM4TP53CASP3 | |
| SCHEMBL30466803 | 0.86 | EPHX2 (0.47) | EPHX2KMT2AMDM4TP53CASP3 | |
| SCHEMBL20530636 | 0.86 | EPHX2 (0.47) | EPHX2KMT2AMDM4TP53CASP3 | |
| SCHEMBL20530666 | 0.85 | RBP4 (0.41) | EPHX2KMT2AP2RX7KDM4ELMNA | |
| SCHEMBL20530648 | 0.84 | EPHX2 (0.40) | EPHX2KMT2AMDM2 | |
| SCHEMBL20530646 | 0.84 | PTGDR2 (0.41) | EPHX2KMT2AMDM2 | |
| SCHEMBL30466808 | 0.84 | EPHX2 (0.40) | EPHX2KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110494442-B | Peptide macrocycles and their use in the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-3609905-B1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2022-06-08 | — | — | EP | disclosed |
| EP-3609905-B1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2022-06-08 | — | — | EP | disclosed |
| US-11091514-B2 | Peptide macrocycles and use thereof in the treatment of bacterial infections | HOFFMANN-LA ROCHE INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091514-B2 | Peptide macrocycles and use thereof in the treatment of bacterial infections | HOFFMANN-LA ROCHE INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3609905-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | H. Hoffnabb-La Roche Ag (CH) | 2020-02-19 | — | — | EP | disclosed |
| US-20200040032-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20200040032-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 2020-02-06 | — | — | US | disclosed |
| WO-2018189063-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-10-18 | — | — | WO | disclosed |
| EP-3388445-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2018-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091514-B2 | Peptide macrocycles and use thereof in the treatment of bacterial infections | VIP, NPY5R, CXCR3 | EPHX2 3891/4885KMT2A 4691/4885P2RX7 330/4885 |
| US-20200040032-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | VIP, NPY5R, CXCR3 | EPHX2 3891/4885KMT2A 4691/4885P2RX7 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.